person · Reporting owner

VAN NOSTRAND ROBERT L

Disclosed activity across 5 companies

Tapewire entity: 69643
SEC CIK: 0001225198

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Enumeral Biomedical Holdings, Inc.ENUM · Entity 179878	Director	January 03, 2017	January 05, 2017
SELLAS Life Sciences Group, Inc.SLS · Entity 4313	Director	January 07, 2026	January 09, 2026
YIELD10 BIOSCIENCE, INC.YTEN · Entity 88195	Director	March 28, 2024	April 01, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Enumeral Biomedical Holdings, Inc.

Report date January 03, 2017 · Filed January 05, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	268,121	Reported balance After 2017-01-03 transaction · row 1 1 source row Row 1 · 2017-01-03 · Grant · Acquired 66,666 · Balance 268,121 F1: Represents a restricted stock award granted by Enumeral Biomedical Holdings, Inc. (the "Company") pursuant to its non-employee director compensation program and the Company's 2014 Equity Incentive Plan, as amended. The restrictions on the shares underlying this award lapse in 4 quarterly installments on each of January 3, 2017, April 1, 2017, July 1, 2017, and October 1, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a restricted stock award granted by Enumeral Biomedical Holdings, Inc. (the "Company") pursuant to its non-employee director compensation program and the Company's 2014 Equity Incentive Plan, as amended. The restrictions on the shares underlying this award lapse in 4 quarterly installments on each of January 3, 2017, April 1, 2017, July 1, 2017, and October 1, 2017.

SELLAS Life Sciences Group, Inc.

Report date January 07, 2026 · Filed January 09, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	82,900	Reported balance After 2026-01-07 transaction · row 1 1 source row Row 1 · 2026-01-07 · Grant · Acquired 50,000 · Balance 82,900 F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

Filing footnotes · ownership attribution and instrument terms

F1: The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date.

YIELD10 BIOSCIENCE, INC.

Report date March 28, 2024 · Filed April 01, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	48,635	Reported balance After 2024-03-28 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2024-03-28 · Grant · Acquired 11,924 · Balance 48,635 F1: Shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2024.

Filing footnotes · ownership attribution and instrument terms

F1: Shares were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2024.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ACHILLION PHARMACEUTICALS INC

Report date January 28, 2020 · Filed January 29, 2020

Section 16 reporting ended · disclosed 2020-01-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-01-28 transaction · row 1 1 source row Row 1 · 2020-01-28 · Disposition to issuer · Disposed 40,000 · Balance 0 F1: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.59 · Expires 2021-12-12	Direct	Reported balance After 2020-01-28 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-01-28 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.54 · Expires 2026-01-25	Direct	Reported balance After 2020-01-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.09 · Expires 2027-01-19	Direct	Reported balance After 2020-01-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2020-12-16	Direct	Reported balance After 2020-01-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-01-28 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.02 · Expires 2023-12-17	Direct	Reported balance After 2020-01-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-01-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2028-02-09	Direct	Reported balance After 2020-01-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-01-28 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.18 · Expires 2029-01-23	Direct	Reported balance After 2020-01-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-01-28 · Disposition to issuer · Disposed 42,000 · Balance 0 F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471.

F2: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor.

Intra-Cellular Therapies, Inc.

Report date April 02, 2025 · Filed April 02, 2025

Section 16 reporting ended · disclosed 2025-04-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2025-04-02 transaction · row 1 1 source row Row 1 · 2025-04-02 · Disposition to issuer · Disposed 11,340 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time"). F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.58 · Expires 2025-06-15	Direct	Reported balance After 2025-04-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.35 · Expires 2026-06-13	Direct	Reported balance After 2025-04-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.39 · Expires 2028-06-17	Direct	Reported balance After 2025-04-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.02 · Expires 2030-05-26	Direct	Reported balance After 2025-04-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $43.45 · Expires 2031-06-20	Direct	Reported balance After 2025-04-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2025-04-02 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $55.48 · Expires 2032-06-08	Direct	Reported balance After 2025-04-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2025-04-02 · Disposition to issuer · Disposed 16,757 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.79 · Expires 2033-06-22	Direct	Reported balance After 2025-04-02 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2025-04-02 · Disposition to issuer · Disposed 7,009 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $67.77 · Expires 2034-06-13	Direct	Reported balance After 2025-04-02 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2025-04-02 · Disposition to issuer · Disposed 4,322 · Balance 0 F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2025-04-02 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2025-04-02 · Disposition to issuer · Disposed 2,951 · Balance 0 F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share. F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances. F7: Not applicable.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated January 10, 2025 (the "Merger Agreement"), by and among Intra-Cellular Therapies, Inc. (the "Company"), Johnson & Johnson, a New Jersey corporation ("Parent"), and Fleming Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which, subject to the terms and conditions thereof, Merger Sub merged with and into the Company (the "Merger"), with the Company surviving the Merger as a wholly owned subsidiary of Parent, effective as of April 2, 2025 (the "Effective Time").

F2: (Continued from Footnote 1) At the Effective Time, each share of common stock, par value $0.0001 per share, of the Company ("Company Shares") issued and outstanding immediately prior to the Effective Time (other than certain Company Shares canceled pursuant to the Merger Agreement and Company Shares with respect to which appraisal rights had been properly and validly exercised) was automatically converted into the right to receive an amount equal to $132.00 per share in cash (the "Merger Consideration"), without interest thereon and less any applicable tax withholdings.

F3: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each option to purchase Company Shares (each, a "Company Option") that was then outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, and which had a per share exercise price that was less than the Merger Consideration, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.

F4: (Continued from Footnote 3) In addition, upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each other Company Option with a per share exercise price that equaled or exceeded the amount of the Merger Consideration was canceled for no consideration.

F5: Each restricted stock unit (each, a "Company RSU") represented a contingent right to receive one Company Share.

F6: Upon the terms and subject to the conditions set forth in the Merger Agreement, at the Effective Time, each Company RSU that was then outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash (without interest) equal to the product of (i) the aggregate number of Company Shares underlying such Company RSU immediately prior to the Effective Time and (ii) the Merger Consideration. Notwithstanding the foregoing, in the case of each Company RSU granted in 2025, the Merger Consideration will instead be payable at the time the original Company RSU would have vested, subject to accelerated vesting in certain circumstances.

F7: Not applicable.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 30, 2022 Filed Oct 5, 2022 16:04 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	110	$46.53	$5,118.30	Disclosure SEC source: 0001209191-22-052716 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,153 Read SEC document
August 11, 2022 Filed Aug 12, 2022 18:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $13.05	$0.00	Disclosure SEC source: 0001209191-22-045685 · doc4.xml · derivative · entry 6 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document
August 11, 2022 Filed Aug 12, 2022 18:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $12.45	$0.00	Disclosure SEC source: 0001209191-22-045685 · doc4.xml · derivative · entry 5 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2027-06-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All shares underlying this option have vested. Read SEC document
August 11, 2022 Filed Aug 12, 2022 18:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	1,500	$56.80	$85,200.00	Disclosure SEC source: 0001209191-22-045685 · doc4.xml · nonDerivative · entry 4 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,043 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.775 to $56.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
August 11, 2022 Filed Aug 12, 2022 18:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	SaleCommon Stock	28,500	$57.15	$1,628,775.00	Disclosure SEC source: 0001209191-22-045685 · doc4.xml · nonDerivative · entry 3 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,543 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.825 to $57.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document
August 11, 2022 Filed Aug 12, 2022 18:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	10,000	$13.05	$130,500.00	Disclosure SEC source: 0001209191-22-045685 · doc4.xml · nonDerivative · entry 2 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 11, 2022 Filed Aug 12, 2022 18:09 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	Exercise / conversionCommon Stock	20,000	$12.45	$249,000.00	Disclosure SEC source: 0001209191-22-045685 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,043 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 30, 2022 Filed Jul 1, 2022 16:46 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	2,134	$2.12 Strike: $2.25	$4,524.08	Disclosure SEC source: 0001121702-22-000030 · wf-form4_165670837395692.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,134 Underlying: Stock Option (right to buy) · 2,134 shares Expires 2032-06-30 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the second quarter of 2022. Read SEC document
June 30, 2022 Filed Jul 5, 2022 16:08 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	108	$57.08	$6,164.64	Disclosure SEC source: 0001209191-22-040571 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,043 Read SEC document
June 09, 2022 Filed Jun 13, 2022 17:01 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantStock Option (right to buy) · Derivative	16,757	$0.00 Strike: $55.48	$0.00	Disclosure SEC source: 0001209191-22-036372 · doc4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,757 Underlying: Common Stock · 16,757 shares Expires 2032-06-08 Read SEC document
May 25, 2022 Filed May 26, 2022 09:18 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $2.69	$0.00	Disclosure SEC source: 0001179110-22-003144 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2032-05-25 F1 · shares: These options were granted to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors. F2 · derivative.exercise_date: These options will vest and become exercisable in equal quarterly installments over 4 years from 5/25/2022, beginning on 8/25/2022 and ending on 5/25/2026. Read SEC document
March 31, 2022 Filed Apr 4, 2022 17:41 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	908	$4.99 Strike: $5.30	$4,530.92	Disclosure SEC source: 0001179110-22-002550 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 908 Underlying: Common Stock · 908 shares Expires 2032-03-31 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2022. Read SEC document
March 31, 2022 Filed Apr 4, 2022 16:11 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	126	$61.19	$7,709.94	Disclosure SEC source: 0001209191-22-022323 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,935 Read SEC document
January 31, 2022 Filed Feb 1, 2022 17:06 UTC	SELLAS Life Sciences Group, Inc. SLS · Entity 4313	GrantStock Option (Right to Buy) · Derivative	7,125	$0.00 Strike: $5.34	$0.00	Disclosure SEC source: 0001104659-22-010397 · tm225088-4_4seq1.xml · derivative · entry 2 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,125 Underlying: Common Stock · 7,125 shares Expires 2032-01-31 F2 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) January 31, 2023 (the first anniversary of the date of grant) or (y) the business day prior to the 2023 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document
January 31, 2022 Filed Feb 1, 2022 17:06 UTC	SELLAS Life Sciences Group, Inc. SLS · Entity 4313	GrantCommon Stock	1,900	$0.00	$0.00	Disclosure SEC source: 0001104659-22-010397 · tm225088-4_4seq1.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,900 F1 · shares: The Reporting Person received an award of 1,900 restricted stock units on January 31, 2022, which shall vest in full on December 1, 2022, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document
December 31, 2021 Filed Jan 3, 2022 16:48 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	976	$4.64 Strike: $4.92	$4,528.64	Disclosure SEC source: 0001179110-22-000015 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 976 Underlying: Common Stock · 976 shares Expires 2031-12-31 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the fourth quarter of 2021. Read SEC document
December 31, 2021 Filed Jan 4, 2022 21:52 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	148	$52.34	$7,746.32	Disclosure SEC source: 0001209191-22-001347 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,809 Read SEC document
September 30, 2021 Filed Oct 4, 2021 14:53 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	801	$5.66 Strike: $5.99	$4,533.66	Disclosure SEC source: 0001179110-21-009134 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 801 Underlying: Common Stock · 801 shares Expires 2031-09-30 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2021. Read SEC document
September 30, 2021 Filed Oct 4, 2021 16:23 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	215	$37.28	$8,015.20	Disclosure SEC source: 0001209191-21-058949 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,661 Read SEC document
June 30, 2021 Filed Jul 1, 2021 16:23 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	562	$8.06 Strike: $8.53	$4,529.72	Disclosure SEC source: 0001179110-21-007250 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 562 Underlying: Common Stock · 562 shares Expires 2031-06-30 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the second quarter of 2021. Read SEC document
June 30, 2021 Filed Jul 2, 2021 16:55 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	173	$40.82	$7,061.86	Disclosure SEC source: 0001209191-21-045038 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,446 Read SEC document
June 21, 2021 Filed Jun 22, 2021 16:19 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $43.45	$0.00	Disclosure SEC source: 0001209191-21-042386 · doc4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-06-20 Read SEC document
May 24, 2021 Filed May 26, 2021 09:59 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $7.96	$0.00	Disclosure SEC source: 0001179110-21-005917 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2031-05-24 F1 · shares: These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof. F2 · derivative.exercise_date: These options will vest and become exercisable in equal quarterly installments over 4 years from 5/24/2021, beginning on 8/24/2021 and ending on 5/24/2025. Read SEC document
March 31, 2021 Filed Apr 2, 2021 11:19 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	383	$11.84 Strike: $12.54	$4,534.72	Disclosure SEC source: 0001179110-21-004027 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383 Underlying: Common Stock · 383 shares Expires 2031-03-31 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2021. Read SEC document
March 31, 2021 Filed Apr 2, 2021 17:26 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	208	$33.93	$7,057.44	Disclosure SEC source: 0001209191-21-024723 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,273 Read SEC document
March 04, 2021 Filed Mar 8, 2021 16:28 UTC	SELLAS Life Sciences Group, Inc. SLS · Entity 4313	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $8.00	$0.00	Disclosure SEC source: 0001104659-21-033296 · tm218923d4_4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-03-04 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 4, 2022 (the first anniversary of the date of grant) or (y) the business day prior to the 2022 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document
December 31, 2020 Filed Jan 4, 2021 19:10 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	818	$5.54 Strike: $5.78	$4,531.72	Disclosure SEC source: 0001179110-21-000068 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 818 Underlying: Common Stock · 818 shares Expires 2030-12-31 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the fourth quarter of 2020. Read SEC document
December 31, 2020 Filed Jan 5, 2021 18:05 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	222	$31.80	$7,059.60	Disclosure SEC source: 0001209191-21-001503 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,065 Read SEC document
September 30, 2020 Filed Oct 2, 2020 11:04 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	624	$7.26 Strike: $7.77	$4,530.24	Disclosure SEC source: 0001179110-20-010076 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 624 Underlying: Common Stock · 624 shares Expires 2030-09-30 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2020. Read SEC document
September 30, 2020 Filed Oct 2, 2020 16:24 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	276	$25.66	$7,082.16	Disclosure SEC source: 0001209191-20-053136 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,843 Read SEC document
June 30, 2020 Filed Jul 2, 2020 13:02 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	777	$5.84 Strike: $6.26	$4,537.68	Disclosure SEC source: 0001179110-20-007866 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 777 Underlying: Common Stock · 777 shares Expires 2030-06-30 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as amember of its Board of Directors and/or a committee thereof during the second quarter of 2020. Read SEC document
June 30, 2020 Filed Jul 2, 2020 19:12 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	275	$25.67	$7,059.25	Disclosure SEC source: 0001209191-20-040693 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,567 Read SEC document
May 28, 2020 Filed May 29, 2020 15:58 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $5.86	$0.00	Disclosure SEC source: 0001179110-20-006710 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2030-05-28 F1 · shares: These options were issued to the Reporting Person as the annual option grant to non-employee directors pursuant to the Issuer's Director Compensation Policy for services to be rendered to the Issuer as a member of its Board of Directors and/or a committee thereof. F2 · derivative.exercise_date: These options will vest and become exercisable in equal quarterly installments over 4 years from 5/28/2020, beginning on 8/28/2020 and ending on 5/28/2024. Read SEC document
May 27, 2020 Filed May 28, 2020 19:13 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantStock Option (right to buy) · Derivative	20,000	$0.00 Strike: $22.02	$0.00	Disclosure SEC source: 0001209191-20-032745 · doc4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-05-26 Read SEC document
March 31, 2020 Filed Apr 2, 2020 16:34 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	1,294	$3.50 Strike: $3.77	$4,529.00	Disclosure SEC source: 0001179110-20-004502 · edgar.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,294 Underlying: Common Stock · 1,294 shares Expires 2030-03-31 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the first quarter of 2020. F2 · shares: All share numbers reported reflect the 1-for-40 reverse stock split effected on January 15, 2020. Read SEC document
March 31, 2020 Filed Apr 2, 2020 17:55 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	460	$15.37	$7,070.20	Disclosure SEC source: 0001209191-20-022753 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,292 Read SEC document
March 12, 2020 Filed Mar 16, 2020 21:19 UTC	SELLAS Life Sciences Group, Inc. SLS · Entity 4313	GrantStock Option (Right to Buy) · Derivative	6,500	$0.00 Strike: $1.89	$0.00	Disclosure SEC source: 0001104659-20-034288 · tm2012902-4_form4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,500 Underlying: Common Stock · 6,500 shares Expires 2030-03-12 F1 · derivative.exercise_date: The shares subject to the option will fully vest on the earlier of (x) March 12, 2021 (the first anniversary of the date of grant) or (y) the business day prior to the 2021 annual stockholders meeting, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. Read SEC document
January 28, 2020 Filed Jan 29, 2020 16:16 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Options (Right to buy) · Derivative	42,000	Not disclosed Strike: $2.18	Not disclosed	Disclosure SEC source: 0001562180-20-000677 · primarydocument.xml · derivative · entry 8 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,000 shares Expires 2029-01-23 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 16:16 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Options (Right to buy) · Derivative	30,000	Not disclosed Strike: $2.90	Not disclosed	Disclosure SEC source: 0001562180-20-000677 · primarydocument.xml · derivative · entry 7 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2028-02-09 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 16:16 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Options (Right to buy) · Derivative	25,000	Not disclosed Strike: $3.02	Not disclosed	Disclosure SEC source: 0001562180-20-000677 · primarydocument.xml · derivative · entry 6 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2023-12-17 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 16:16 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Options (Right to buy) · Derivative	50,000	Not disclosed Strike: $3.10	Not disclosed	Disclosure SEC source: 0001562180-20-000677 · primarydocument.xml · derivative · entry 5 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2020-12-16 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 16:16 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Options (Right to buy) · Derivative	30,000	Not disclosed Strike: $4.09	Not disclosed	Disclosure SEC source: 0001562180-20-000677 · primarydocument.xml · derivative · entry 4 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2027-01-19 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 16:16 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Options (Right to buy) · Derivative	30,000	Not disclosed Strike: $7.54	Not disclosed	Disclosure SEC source: 0001562180-20-000677 · primarydocument.xml · derivative · entry 3 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2026-01-25 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 16:16 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerStock Options (Right to buy) · Derivative	20,000	Not disclosed Strike: $7.59	Not disclosed	Disclosure SEC source: 0001562180-20-000677 · primarydocument.xml · derivative · entry 2 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2021-12-12 F2 · price: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. F2 · derivative.exercise_date: Subject to certain conditions, at the effective time, all unexercised options with an exercise price below $6.30 were cancelled and converted into the right to receive (i) a cash payment of (A) $6.30 less the exercise price, multiplied by (B) the number of shares subject thereto and (ii) one CVR per share subject thereto. Options with an exercise price of $6.30 or greater were cancelled and converted into the right to receive a cash payment with respect to each share subject thereto upon each milestone payment date equal to (i) the amount by which, as of the payment date, the sum of (x) $6.30, (y) the amount per share previously paid in respect of any earlier payment date and (z) the amount in cash to be paid at such payment date exceeds the exercise price payable under such option, less (ii) the amount of all payments previously received with respect to such option. Options with an exercise price of $8.30 or greater were cancelled without any consideration payable therefor. Read SEC document
January 28, 2020 Filed Jan 29, 2020 16:16 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Disposition to issuerCommon Stock	40,000	$6.30	$252,000.00	Disclosure SEC source: 0001562180-20-000677 · primarydocument.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to the merger agreement (the "Merger Agreement") among Achillion Pharmaceuticals, Inc. ("Achillion"), Alexion Pharmaceuticals, Inc. ("Alexion") and Beagle Merger Sub, Inc. In addition to the cash consideration of $6.30 per share, each shareholder will also receive one contingent value right ("CVR") per share. Each CVR represents the right to receive contingent cash payments of $1.00 upon the achievement of a certain clinical trial milestone with respect to ACH-5228 and $1.00 upon the achievement of a certain regulatory approval milestone with respect to ACH-4471. Read SEC document
December 31, 2019 Filed Jan 3, 2020 21:13 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	170	$34.31	$5,832.70	Disclosure SEC source: 0001209191-20-001464 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,832 Read SEC document
December 18, 2019 Filed Dec 19, 2019 17:33 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Exercise / conversionStock Option (Right to Buy) · Derivative	20,000	$0.00 Strike: $3.28	$0.00	Disclosure SEC source: 0001562180-19-006193 · primarydocument.xml · derivative · entry 2 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2019-12-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on December 18, 2009 and vested over a four year period with 25% of the shares vesting on the first anniversary of the grant date and an additional 6.25% vesting at the end of each three-month period thereafter. Read SEC document
December 18, 2019 Filed Dec 19, 2019 17:33 UTC	ACHILLION PHARMACEUTICALS INC ACHN · Entity 12234	Exercise / conversionCommon Stock	20,000	$3.28	$65,600.00	Disclosure SEC source: 0001562180-19-006193 · primarydocument.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 30, 2019 Filed Oct 2, 2019 18:18 UTC	YIELD10 BIOSCIENCE, INC. YTEN · Entity 88195	GrantStock Option (right to buy) · Derivative	9,845	$0.46 Strike: $0.50	$4,528.70	Disclosure SEC source: 0001104659-19-052674 · a4.xml · derivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,845 Underlying: Common Stock · 9,845 shares Expires 2029-09-30 F1 · shares: These options were issued to the Reporting Person pursuant to the Issuer's Director Compensation Policy in lieu of $4,531 of cash compensation for services rendered to the Issuer as a member of its Board of Directors and/or a committee thereof during the third quarter of 2019. Read SEC document
September 30, 2019 Filed Oct 2, 2019 17:32 UTC	Intra-Cellular Therapies, Inc. ITCI · Entity 81206	GrantCommon Stock	780	$7.47	$5,826.60	Disclosure SEC source: 0001209191-19-051853 · doc4.xml · nonDerivative · entry 1 VAN NOSTRAND ROBERT L · CIK 0001225198 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,662 Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.